CA3099089A1 - Neurosteroid derivatives and uses thereof - Google Patents

Neurosteroid derivatives and uses thereof Download PDF

Info

Publication number
CA3099089A1
CA3099089A1 CA3099089A CA3099089A CA3099089A1 CA 3099089 A1 CA3099089 A1 CA 3099089A1 CA 3099089 A CA3099089 A CA 3099089A CA 3099089 A CA3099089 A CA 3099089A CA 3099089 A1 CA3099089 A1 CA 3099089A1
Authority
CA
Canada
Prior art keywords
pharmaceutical composition
mixture
ganaxolone
subject
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3099089A
Other languages
English (en)
French (fr)
Inventor
Nathan Bryson
Avinash Chander Sharma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acerus Pharmaceuticals Corp
Original Assignee
Acerus Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acerus Pharmaceuticals Corp filed Critical Acerus Pharmaceuticals Corp
Publication of CA3099089A1 publication Critical patent/CA3099089A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/009—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by only one oxygen atom doubly bound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0007—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
    • C07J5/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3099089A 2018-05-04 2019-05-03 Neurosteroid derivatives and uses thereof Pending CA3099089A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862667100P 2018-05-04 2018-05-04
US62/667,100 2018-05-04
US16/403,100 2019-05-03
US16/403,100 US20190337975A1 (en) 2018-05-04 2019-05-03 Neurosteroid derivatives and uses thereof
PCT/IB2019/000517 WO2019211668A2 (en) 2018-05-04 2019-05-03 Neurosteroid derivatives and uses thereof

Publications (1)

Publication Number Publication Date
CA3099089A1 true CA3099089A1 (en) 2019-11-07

Family

ID=68384780

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3099089A Pending CA3099089A1 (en) 2018-05-04 2019-05-03 Neurosteroid derivatives and uses thereof

Country Status (11)

Country Link
US (2) US20190337975A1 (https=)
EP (1) EP3788055A4 (https=)
JP (1) JP2021523938A (https=)
CN (1) CN112823164A (https=)
AR (1) AR116659A1 (https=)
AU (1) AU2019264032A1 (https=)
CA (1) CA3099089A1 (https=)
PY (1) PY1934080A (https=)
TW (1) TW202014192A (https=)
UY (1) UY38213A (https=)
WO (1) WO2019211668A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201606063RA (en) 2012-01-23 2016-09-29 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
MX2015002252A (es) 2012-08-21 2015-07-21 Sage Therapeutics Inc Metodos para tratar epilepsia o estado de epilepsia.
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
JP6470258B2 (ja) 2013-04-17 2019-02-13 セージ セラピューティクス， インコーポレイテッド １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法
ES2848823T3 (es) 2013-08-23 2021-08-12 Sage Therapeutics Inc Esteroides neuroactivos, composiciones y usos de los mismos
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
US10577390B2 (en) 2014-10-16 2020-03-03 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
ME03809B (me) 2014-10-16 2021-04-20 Sage Therapeutics Inc KOMPOZICIJE I POSTUPCI ZA LEČENJE POREMEĆAJA CNS-a
WO2016123056A1 (en) 2015-01-26 2016-08-04 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
HK1258616A1 (zh) 2016-03-08 2019-11-15 Sage Therapeutics, Inc. 神经活性类固醇、组合物、及其用途
US20190233465A1 (en) 2016-07-11 2019-08-01 Sage Therapeutics, Inc. C7, c12, and c16 substituted neuroactive steroids and their methods of use
MA45599A (fr) 2016-07-11 2019-05-15 Sage Therapeutics Inc Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation
CR20240234A (es) 2019-05-31 2024-07-09 Sage Therapeutics Inc ESTEROIDES NEUROACTIVOS Y COMPOSICIONES DE ESTOS (Divisional 2021-629)
CN115348864A (zh) * 2020-02-05 2022-11-15 纯技术Lyt股份有限公司 神经甾体的脂质前药
MX2022010620A (es) * 2020-02-27 2022-11-30 Brii Biosciences Inc Profarmacos de esteroides neuroactivos.
IL315509A (en) * 2022-03-18 2024-11-01 Marinus Pharmaceuticals Inc Genaxolone medication matrims

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB748846A (en) * 1953-10-28 1956-05-09 Vitamins Ltd A process for the manufacture of pregnan-3(-a)-ol-20-one and derivatives thereof
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
KR100338287B1 (ko) * 1994-02-14 2002-11-30 푸르듀 파머 리미티드 감마-아미노부티르산a수용체의알로오스테리조절용안드로스탄및프레그난
US20060009432A1 (en) * 2004-07-09 2006-01-12 Roger Whiting Use of neurosteroids to treat neuropathic pain
WO2011120044A1 (en) * 2010-03-26 2011-09-29 Duke University Conjugated neuroactive steroid compositions and methods of use
FR2973031B1 (fr) * 2011-03-23 2013-11-29 Univ Strasbourg Derives de l'allopregnanolone et de l'epiallopregnanolone et leurs utilisations pour traiter un etat neuropathologique
US20170022245A1 (en) * 2013-11-26 2017-01-26 Biopharma Works Ganaxolone derivatives for treatment of central nervous systems disorders
EP3641779B1 (en) * 2017-06-23 2024-02-28 The Board of Trustees of the University of Illinois Treatment of neuropsychiatric disorders with neurosteroids and analogues thereof
CN109666055A (zh) * 2017-10-16 2019-04-23 张家口华健致远生物科技有限公司 调节中枢神经治疗抑郁症的化合物及其用途

Also Published As

Publication number Publication date
WO2019211668A3 (en) 2019-12-12
TW202014192A (zh) 2020-04-16
EP3788055A2 (en) 2021-03-10
UY38213A (es) 2019-10-31
AR116659A1 (es) 2021-06-02
PY1934080A (es) 2019-11-08
AU2019264032A1 (en) 2020-12-03
EP3788055A4 (en) 2022-03-30
US20190337975A1 (en) 2019-11-07
JP2021523938A (ja) 2021-09-09
CN112823164A (zh) 2021-05-18
WO2019211668A2 (en) 2019-11-07
US20210363173A1 (en) 2021-11-25

Similar Documents

Publication Publication Date Title
US20210363173A1 (en) Neurosteriod derivatives and uses thereof
CA2908571C (en) Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives
US6239177B1 (en) Tranilast-containing preparation for external application and method of producing the same
JP2005519985A (ja) 医薬組成物
CA2415349A1 (en) Testosterone ester formulation for human use
CN113018248A (zh) 一种缓释递药系统
US20200188412A1 (en) Active ester derivatives of testosterone, compositions and uses thereof
CN101831067A (zh) 聚乙二醇脂类缀合物及其在制备药物中的应用
JPS6341887B2 (https=)
CN104053437A (zh) 包含蓓萨罗丁和皮质类固醇的局部药物组合物
EP1617827A1 (de) Pharmazeutische zusammensetzung in form eines hydrogels zur transdermalen verabreichung von wirkstoffen
EP1214055A2 (de) Pharmazeutisches, wirkstoffhaltiges gel
CN111481559B (zh) 一种高浓度的氟维司群组合物及其制备方法
JP3538370B2 (ja) 皮膚の色素異常症、瘢痕等の治療用又は予防用外用剤
CN111035613A (zh) 一种包含氟维司群的可注射的药物组合物及其制备方法
AU2019395549B2 (en) Composition comprising dutasteride
DE10203923B4 (de) Verfahren zur Erhöhung der Wasserlöslichkeit lipophiler Wirkstoffe, Herstellung von hochkonzentrierten wässrigen Zusammensetzungen dieser Wirkstoffe, derartige Produkte und ihre Verwendung
CA2244679C (en) Tranilast-containing preparation for external application and method of producing the same
WO2005011669A1 (ja) 経皮投与用医薬組成物
GB2542872A (en) Use of heptyl glucoside as skin penetration enhancer in transdermal pharmaceutical compositions
CN121081362A (zh) 用于运动系统疾病的双氯芬酸钠透皮微针贴剂
EP3192515B1 (de) Pharmazeutische zusammensetzung enthaltend 7beta-hydroxycholesterol geeignet zur intravenösen verabreichung
JP3538367B2 (ja) 皮膚組織障害治療・予防・改善用外用剤
CN101513411A (zh) 齐墩果烷-28-酸-2,11,13(18)-三烯在制备治疗皮肤疾病药物中的应用
CN118267355A (zh) 一种辣椒素的乳剂组合物及其制备方法和应用

Legal Events

Date Code Title Description
R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: N-6-6-R10-R00-R116 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUEST

Effective date: 20240813

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: N-6-6-R10-R00-R119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUEST

Effective date: 20241121

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241121

R17 Change to representative recorded

Free format text: ST27 STATUS EVENT CODE: N-6-6-R10-R17-R117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250107

Free format text: ST27 STATUS EVENT CODE: N-6-6-R10-R17-R121 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250107

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250107